Liao Q, Xiong J
Exp Ther Med. 2024; 27(6):255.
PMID: 38682111
PMC: 11046265.
DOI: 10.3892/etm.2024.12543.
Sahab-Negah S, Gorji A
Adv Exp Med Biol. 2021; 1296:33-48.
PMID: 34185285
DOI: 10.1007/978-3-030-59038-3_3.
Eto S, Yanai H, Hangai S, Kato D, Nishimura R, Nakagawa T
Sci Rep. 2021; 11(1):8525.
PMID: 33875721
PMC: 8055655.
DOI: 10.1038/s41598-021-87979-1.
Mondal T, Shivange G, Tihagam R, Lyerly E, Battista M, Talwar D
EMBO Mol Med. 2021; 13(3):e12716.
PMID: 33587338
PMC: 7933954.
DOI: 10.15252/emmm.202012716.
Rao A, Madejska A, Pfeil J, Paten B, Salama S, Haussler D
Front Immunol. 2020; 11:483296.
PMID: 33244314
PMC: 7683782.
DOI: 10.3389/fimmu.2020.483296.
Role of Anillin in Tumour: From a Prognostic Biomarker to a Novel Target.
Tuan N, Lee C
Cancers (Basel). 2020; 12(6).
PMID: 32560530
PMC: 7353083.
DOI: 10.3390/cancers12061600.
Role of Sphingosylphosphorylcholine in Tumor and Tumor Microenvironment.
Park M, Lee C
Cancers (Basel). 2019; 11(11).
PMID: 31683697
PMC: 6896196.
DOI: 10.3390/cancers11111696.
Elucidating immunometabolic targets in glioblastoma.
Agarwal P, Pajor M, Anson D, Guda M, Labak C, Tsung A
Am J Cancer Res. 2017; 7(10):1990-1995.
PMID: 29119048
PMC: 5665846.
INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
Yu Y, Huang R, Zong X, He X, Mo W
BMC Cancer. 2016; 16:397.
PMID: 27389040
PMC: 4936163.
DOI: 10.1186/s12885-016-2473-0.
Inducing and Administering Tregs to Treat Human Disease.
Perdigoto A, Chatenoud L, Bluestone J, Herold K
Front Immunol. 2016; 6:654.
PMID: 26834735
PMC: 4722090.
DOI: 10.3389/fimmu.2015.00654.
Anti-α-enolase is a prognostic marker in postoperative lung cancer patients.
Hsiao K, Shih N, Chu P, Hung Y, Liao J, Chou S
Oncotarget. 2015; 6(33):35073-86.
PMID: 26551021
PMC: 4741510.
DOI: 10.18632/oncotarget.5316.
Relationships between tumor microenvironment and clinicopathological parameters in meningioma.
Ding Y, Qiu L, Xu Q, Song L, Yang S, Yang T
Int J Clin Exp Pathol. 2014; 7(10):6973-9.
PMID: 25400783
PMC: 4230127.
Dendritic cell cancer vaccines: from the bench to the bedside.
Katz T, Avivi I, Benyamini N, Rosenblatt J, Avigan D
Rambam Maimonides Med J. 2014; 5(4):e0024.
PMID: 25386340
PMC: 4222413.
DOI: 10.5041/RMMJ.10158.
Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing.
Madsen C, Lavrsen K, Steentoft C, Vester-Christensen M, Clausen H, Wandall H
PLoS One. 2013; 8(9):e72413.
PMID: 24039759
PMC: 3765166.
DOI: 10.1371/journal.pone.0072413.
Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander?.
DArena G, Simeon V, DAuria F, Statuto T, Di Sanzo P, De Martino L
Am J Blood Res. 2013; 3(1):52-7.
PMID: 23358515
PMC: 3555189.
Role of macrophage migration inhibitory factor in the regulatory T cell response of tumor-bearing mice.
Choi S, Kim H, Leng L, Kang I, Jorgensen W, Cho C
J Immunol. 2012; 189(8):3905-13.
PMID: 22972922
PMC: 3466372.
DOI: 10.4049/jimmunol.1102152.
Cellular constituents of immune escape within the tumor microenvironment.
Kerkar S, Restifo N
Cancer Res. 2012; 72(13):3125-30.
PMID: 22721837
PMC: 6327310.
DOI: 10.1158/0008-5472.CAN-11-4094.
High-anxious individuals show increased chronic stress burden, decreased protective immunity, and increased cancer progression in a mouse model of squamous cell carcinoma.
Dhabhar F, Saul A, Holmes T, Daugherty C, Neri E, Tillie J
PLoS One. 2012; 7(4):e33069.
PMID: 22558071
PMC: 3338811.
DOI: 10.1371/journal.pone.0033069.
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors.
Draghiciu O, Nijman H, Daemen T
Clin Dev Immunol. 2011; 2011:439053.
PMID: 22190971
PMC: 3235497.
DOI: 10.1155/2011/439053.
In Vivo Modulation of Dendritic Cells by Engineered Materials: Towards New Cancer Vaccines.
Kim J, Mooney D
Nano Today. 2011; 6(5):466-477.
PMID: 22125572
PMC: 3224090.
DOI: 10.1016/j.nantod.2011.08.005.
